Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

Research output: Contribution to journalJournal articleResearchpeer-review

  1. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

    Research output: Contribution to journalReviewResearchpeer-review

  4. Natural History of Histologically-proven Alcohol Related Liver Disease: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background & Aims: Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF. Methods: A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded. Results: Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC). Conclusions: Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. ClinicalTrials.gov number: NCT03056612. Lay summary: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death – termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD – patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.

Original languageEnglish
JournalJournal of Hepatology
Volume73
Issue number4
Pages (from-to)842-854
Number of pages13
ISSN0168-8278
DOIs
Publication statusPublished - Oct 2020

    Research areas

  • Acute complications, Chronic liver disease, Non-elective admission, Outcome, Risk factors

ID: 60405875